A retrospective study assessing the incidence of thromboembolism in patients with lung cancer treated with immune checkpoint inhibitors (ICIs)
Latest Information Update: 04 Feb 2022
At a glance
- Drugs Atezolizumab (Primary) ; Avelumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Lung cancer
- Focus Adverse reactions
Most Recent Events
- 04 Feb 2022 New trial record
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition